Literature DB >> 30316548

The Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE) tool predicts reduction in sedentary time following pulmonary rehabilitation in people with chronic obstructive pulmonary disease (COPD).

Athina Liacos1, Christine F McDonald2, Ajay Mahal3, Catherine J Hill4, Annemarie L Lee5, Angela T Burge5, Rosemary Moore6, Caroline Nicolson1, Paul O'Halloran7, Narelle S Cox8, Aroub Lahham8, Rebecca Gillies7, Anne E Holland9.   

Abstract

OBJECTIVES: To examine the predictive validity, minimal important difference (MID) and responsiveness of the PRAISE tool.
DESIGN: Retrospective data analysis from HomeBase trial of home vs centre-based pulmonary rehabilitation.
SETTING: Tertiary health service. PARTICIPANTS: One hundred and sixty-six participants with COPD (100 men) with mean age 69 (SD 9) years, FEV1% predicted 50% (19).
INTERVENTIONS: Eight-week pulmonary rehabilitation program, conducted at the hospital or at home. MAIN OUTCOME MEASURES: The 15-item PRAISE tool comprising 10 general and five pulmonary rehabilitation-specific self-efficacy questions. Predictive validity was examined by exploring the relationship between baseline PRAISE score and objective change in physical activity following pulmonary rehabilitation using the SenseWear Armband. The MID was evaluated using anchor-based and distribution-based methods. Responsiveness was assessed with effect sizes.
RESULTS: A higher baseline PRAISE score (indicating better self-efficacy) was an independent predictor of reduced sedentary time following pulmonary rehabilitation (P=0.03). A one point increase in PRAISE was associated with a decrease in sedentary time of 4minutes/day (95% confidence interval -7.8 to -0.4minutes/day). Anchor-based estimates of the MID were 0.5 to 1.5 points; however sensitivity and specificity were modest (area under the curve <0.70). Change in PRAISE score following pulmonary rehabilitation had an effect size of 0.21.
CONCLUSIONS: The PRAISE tool has predictive validity and may be useful to identify those with high self-efficacy who are more likely to achieve important health behaviour changes with pulmonary rehabilitation. The small effect size suggests that the PRAISE tool was not responsive to changes following pulmonary rehabilitation. TRIAL REGISTRATION NUMBER: NCT01423227, clinicaltrials.gov.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Health behaviour; Physical activity; Pulmonary disease, chronic obstructive; Self-efficacy

Mesh:

Year:  2018        PMID: 30316548     DOI: 10.1016/j.physio.2018.07.009

Source DB:  PubMed          Journal:  Physiotherapy        ISSN: 0031-9406            Impact factor:   3.358


  5 in total

1.  Long-term effects of web-based pedometer-mediated intervention on COPD exacerbations.

Authors:  Emily S Wan; Ana Kantorowski; Madeline Polak; Reema Kadri; Caroline R Richardson; David R Gagnon; Eric Garshick; Marilyn L Moy
Journal:  Respir Med       Date:  2020-01-11       Impact factor: 3.415

2.  Digital interventions for the management of chronic obstructive pulmonary disease.

Authors:  Sadia Janjua; Emma Banchoff; Christopher Jd Threapleton; Samantha Prigmore; Joshua Fletcher; Rebecca T Disler
Journal:  Cochrane Database Syst Rev       Date:  2021-04-19

3.  Patterns and correlates of sedentary behaviour among people with multiple sclerosis: a cross-sectional study.

Authors:  Jennifer Fortune; Meriel Norris; Andrea Stennett; Cherry Kilbride; Grace Lavelle; Wendy Hendrie; Christina Victor; Jennifer Mary Ryan
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

4.  Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD).

Authors:  Angela T Burge; Narelle S Cox; Michael J Abramson; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2020-04-16

Review 5.  Self-Efficacy Intervention Programs in Patients with Chronic Obstructive Pulmonary Disease: Narrative Review.

Authors:  Qi-Feng Yi; Guo-Li Yang; Jin Yan
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.